ASH 2019

Showing 2 posts of 2 posts found.

abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …

jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …

Latest content